Daniel Lundquist

All right. Thank you, everybody, for joining Day 2 here at the Bank of America Healthcare Conference. I'm Dan Lundquist, the health care specialist, very pleased today to have the team from Pulse Biosciences, where I'm joined on stage here by CEO, Paul LaViolette. CFO, Jon Skinner, is in the audience as well. They have a presentation which they'll run through. We have time. I have a couple of questions. But over to you, Paul. Thank you.

Paul LaViolette
President, CEO & Co-Chairman of the Board

Thank you very much, and great to be joined by Jon and everyone interested in the Pulse Biosciences story. I'll be making forward-looking statements today, and this is our disclosure.

And so let's get into the actual story of our mission. We are a company dedicated exclusively to the development and delivery of a novel energy form Nanosecond Pulsed Field Ablation, which also delivers a novel mechanism of action, which is the generation of the regulated cell death process. It's a very novel approach, and we'll address many ablation opportunities, which we'll talk about.

As a company, we're very focused on the rigor of data generation. We have multiple clinical trials underway. We'll talk about those momentarily. And from an opportunity perspective, we're going after a number of significant markets, very large patient populations and the potential to be very disruptive as a next-generation energy opportunity.

The team is extremely strong, anchored by Darrin Uecker. Darrin, our Chief Technology Officer and really a founder of the company, has led the vision for Nanosecond Pulsed Field Ablation since our inception. In